Acton, Massachusetts — October 10, 2025 — Leads & Copy — Bluejay Diagnostics, Inc. has announced the closing of a private placement, securing $4.5 million before fees. The placement involved 2,250,000 shares of common stock and Series F warrants, priced at $2.00 per share, with warrants to purchase up to 4,500,000 shares.
The Series F warrants, exercisable immediately, have a price of $1.75 per share and expire in five and a half years. Rodman and Renshaw LLC acted as the exclusive placement agent.
Bluejay Diagnostics plans to allocate the net proceeds to FDA approval efforts, including clinical studies, research and development, and general working capital.
These securities were offered privately under Section 4(a)(2) of the Securities Act of 1933 and Regulation D and have not been registered under the Securities Act. A resale registration statement will be filed per an agreement with investors.
This announcement does not constitute an offer to sell or a solicitation to buy securities.
Bluejay Diagnostics focuses on improving patient outcomes with its Symphony System, a rapid testing system for sepsis triage and disease monitoring. The company’s lead product, an IL-6 Test for sepsis, aims to deliver results in about 20 minutes.
Investor Relations
Bluejay Diagnostics, Inc.
ir@bluejaydx.com
Source: Bluejay Diagnostics, Inc.
